日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma

TRC105联合索拉非尼治疗肝细胞癌的I期和初步II期研究

Duffy, Austin G; Ma, Chi; Ulahannan, Susanna V; Rahma, Osama E; Makarova-Rusher, Oxana; Cao, Liang; Yu, Yunkai; Kleiner, David E; Trepel, Jane; Lee, Min-Jung; Tomita, Yusuke; Steinberg, Seth M; Heller, Theo; Turkbey, Baris; Choyke, Peter L; Peer, Cody J; Figg, William D; Wood, Brad J; Greten, Tim F

The case for immune-based approaches in biliary tract carcinoma

免疫疗法在胆道癌治疗中的应用

Duffy, Austin G; Makarova-Rusher, Oxana V; Greten, Tim F

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer

反义抑制对肿瘤 eIF4E 的调节:ISIS 183750(一种针对 eIF4E 的反义寡核苷酸)与伊立替康联合用于实体瘤和伊立替康难治性结直肠癌的 I/II 期转化临床试验

A G Duffy, O V Makarova-Rusher, S V Ulahannan, O E Rahma, S Fioravanti, M Walker, S Abdullah, M Raffeld, V Anderson, N Abi-Jaoudeh, E Levy, B J Wood, S Lee, Y Tomita, J B Trepel, S M Steinberg, A S Revenko, A R MacLeod, C J Peer, W D Figg, T F Greten

Pancreatic Squamous Cell Carcinoma: A Population-Based Study of Epidemiology, Clinicopathologic Characteristics and Outcomes

胰腺鳞状细胞癌:一项基于人群的流行病学、临床病理特征和预后研究

Makarova-Rusher, Oxana V; Ulahannan, Susanna; Greten, Tim F; Duffy, Austin

A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib

一项针对索拉非尼治疗后病情进展的肝细胞癌患者的TRC105 II期研究

Duffy, A G; Ulahannan, S V; Cao, L; Rahma, O E; Makarova-Rusher, O V; Kleiner, D E; Fioravanti, S; Walker, M; Carey, S; Yu, Y; Venkatesan, A M; Turkbey, B; Choyke, P; Trepel, J; Bollen, K C; Steinberg, S M; Figg, W D; Greten, T F